Related Experiment Video
Updated: Dec 20, 2025
Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets
Published on: February 2, 2024
Adjuvant therapy in pancreatic cancer
Owain Peris Jones1, James Daniel Melling1, Paula Ghaneh1
1Owain Peris Jones, James Daniel Melling, Paula Ghaneh, Department of Molecular and Clinical Cancer Medicine, University of Liverpool, 5 Floor UCD Building, Daulby Street, Liverpool L69 3GA, United Kingdom.
None:
Pancreatic cancer remains one of the leading causes of cancer related death worldwide with an overall five-year survival of less than 5%. Potentially curative surgery, which alone can improve 5-year survival to 10%, is an option for only 10%-20% of patients at presentation owing to local invasion of the tumour or metastatic disease. Adjuvant chemotherapy has been shown to improve 5-year survival to 20%-25% but conflicting evidence remains with regards to chemoradiation. In this article we review the current evidence available from published randomised trials and discuss ongoing phase III trials in relation to adjuvant therapy in pancreatic cancer.
Related Concept Videos
01:29Chronic Pancreatitis II: Collaborative Care
Assessment:
01:27Tumor Immunotherapy
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:56Treatment Resistant Cancers